Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Biliary Tract Diseases

  Free Subscription

Articles published in Clin Res Hepatol Gastroenterol

Retrieve available abstracts of 48 articles:
HTML format

Single Articles

    May 2023
  1. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    PubMed     Abstract available

    April 2023
  2. SHIAU H, Schraw JM, Mysore K, Cavallo L, et al
    Characteristics of infections and their risk factors in children with biliary atresia.
    Clin Res Hepatol Gastroenterol. 2023;47:102109.
    PubMed     Abstract available

  3. SASAKI M, Sato Y, Nakanuma Y
    An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2023;47:102106.
    PubMed     Abstract available

    December 2022
  4. FERREIRA FB, Mourato M, Braganca S, Paulo JB, et al
    COVID-19-associated secondary sclerosing cholangitis - A case series of 4 patients.
    Clin Res Hepatol Gastroenterol. 2022;46:102048.
    PubMed     Abstract available

  5. NEUZILLET C, Malka D, Lievre A, Khurana IS, et al
    Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review.
    Clin Res Hepatol Gastroenterol. 2022;46:102010.
    PubMed     Abstract available

    November 2022
  6. WASUWANICH P, Choudry H, So JM, Lowry S, et al
    Vanishing bile duct syndrome after drug-induced liver injury.
    Clin Res Hepatol Gastroenterol. 2022;46:102015.
    PubMed     Abstract available

  7. WU L, Yang J, Ke RS, Liu Y, et al
    Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101999.
    PubMed     Abstract available

    October 2022
  8. WANG J, Lun W, Shi W
    Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.
    Clin Res Hepatol Gastroenterol. 2022;46:102013.
    PubMed     Abstract available

  9. BRAN DM, Fuks D, Lansier A, Gallois C, et al
    Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
    Clin Res Hepatol Gastroenterol. 2022;46:101920.

    September 2022
  10. COILLY A, Sebagh M, Fougerou-Leurent C, Pageaux GP, et al
    HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation.
    Clin Res Hepatol Gastroenterol. 2022 Sep 16:102024.
    PubMed     Abstract available

    August 2022
  11. YANG SH, Hu S, Kang Q, Liu LX, et al
    EIF5A2 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells.
    Clin Res Hepatol Gastroenterol. 2022;46:101991.
    PubMed     Abstract available

  12. JIANG H, Li W, Xue Z, Chen W, et al
    lncRNA TM4SF1-AS1 predicts dismal outcomes and promotes cholangiocarcinoma progression via modulating miR-744-3p.
    Clin Res Hepatol Gastroenterol. 2022;46:101915.
    PubMed     Abstract available

    June 2022
  13. NAYAGAM JS, Mandour MO, Taylor A, Heneghan MA, et al
    Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.
    Clin Res Hepatol Gastroenterol. 2022 Jun 18:101980.
    PubMed     Abstract available

    April 2022
  14. JAIN A, Kirkpatrick RB, Sobotka LA
    Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
    Clin Res Hepatol Gastroenterol. 2022;46:101875.

    March 2022
  15. CAMPOS-PEREZ W, Perez-Robles M, Rodriguez-Echevarria R, Rivera-Valdes JJ, et al
    High dietary omega-6:omega-3 PUFA ratio and simple carbohydrates as a potential risk factors for gallstone disease: A cross-sectional study.
    Clin Res Hepatol Gastroenterol. 2022;46:101802.
    PubMed     Abstract available

  16. ADAMS T, Liebe R, Lehmann J, Krawczyk M, et al
    Acute cholestatic liver injury following carbimazole treatment in a patient with VPS33B haploinsufficiency.
    Clin Res Hepatol Gastroenterol. 2022;46:101803.

  17. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
    Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
    Clin Res Hepatol Gastroenterol. 2022;46:101800.
    PubMed     Abstract available

    February 2022
  18. JULIA S, Peter S, Karl-Heinz W, Daniel Nils G, et al
    Possible role of the HMGB1 and RAGE inflammatory pathway in primary sclerosing cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101791.
    PubMed     Abstract available

  19. SONG S, Yang W, Tian H, Gong S, et al
    The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101788.
    PubMed     Abstract available

    January 2022
  20. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
    Non-invasive diagnosis and follow-up of benign liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101765.
    PubMed     Abstract available

  21. CHAZOUILLERES O, Potier P, Bouzbib C, Hanslik B, et al
    Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101775.
    PubMed     Abstract available

  22. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
    Non-invasive diagnosis and follow-up of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101770.
    PubMed     Abstract available

  23. LEMOINNE S, Heurgue A, Bouzbib C, Hanslik B, et al
    Non-invasive diagnosis and follow-up of autoimmune hepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101772.
    PubMed     Abstract available

    November 2021
  24. BOURDELEAU P, Larrey E, Allaire M, Charlotte F, et al
    "De novo" Cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed!
    Clin Res Hepatol Gastroenterol. 2021 Nov 2:101827.
    PubMed     Abstract available

  25. XU ZL, Ou YJ, Dai HS, Wan K, et al
    Elevated preoperative CA125 levels predicts poor prognosis of hilar cholangiocarcinoma receiving radical surgery.
    Clin Res Hepatol Gastroenterol. 2021;45:101695.
    PubMed     Abstract available

  26. REN T, Pang L, Dai W, Wu S, et al
    Regulatory mechanisms of the bile salt export pump (BSEP/ABCB11) and its role in related diseases.
    Clin Res Hepatol Gastroenterol. 2021;45:101641.
    PubMed     Abstract available

  27. ORLOWSKA E, Czubkowski P, Wolochowska K, Jarzebicka D, et al
    Assessment of Lactobacillus casei rhamnosus (LGG) therapy in children with biliary atresia - Randomized placebo controlled trial.
    Clin Res Hepatol Gastroenterol. 2021;45:101753.
    PubMed     Abstract available

  28. LOPEZ DE FRUTOS L, Cebolla JJ, de Castro-Oros I, Irun P, et al
    Neonatal cholestasis and Niemann-pick type C disease: A literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101757.
    PubMed     Abstract available

    September 2021
  29. NAKAMURA H, Ara M, Koga H, Miyano G, et al
    Duration from the first pale stool to portoenterostomy is prognostic in biliary atresia. Comparison with age at portoenterostomy.
    Clin Res Hepatol Gastroenterol. 2021;45:101584.
    PubMed     Abstract available

  30. ZIMMER V
    Intraductal vacuum suction for high biliary stone retrieval during direct cholangioscopy.
    Clin Res Hepatol Gastroenterol. 2021;45:101600.

  31. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
    Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101751.
    PubMed     Abstract available

    July 2021
  32. PERRAULT F, Echelard P, Viens D, Borduas M, et al
    Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
    Clin Res Hepatol Gastroenterol. 2021;45:101475.
    PubMed     Abstract available

    May 2021
  33. ZIMMER V, Reichert MC, Lammert F
    Cholesterol crystals in biliary cast syndrome related to sclerosing cholangitis in critically ill patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101485.

  34. LYKAVIERIS P, Bernard O, Jacquemin E
    Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
    Clin Res Hepatol Gastroenterol. 2021;45:101472.

  35. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
    Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101675.
    PubMed     Abstract available

    March 2021
    The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
    Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.

  37. FAMULARO G, Spada PL
    COVID-19-related cholecystitis.
    Clin Res Hepatol Gastroenterol. 2021;45:101635.

  38. DI GIORGIO A, Nicastro E, Arnaboldi S, Montini O, et al
    "Health status of children with chronic liver disease during the SARS-CoV-2 outbreak: results from a multicentre study".
    Clin Res Hepatol Gastroenterol. 2021;45:101610.

  39. WANG P, Tao H, Liu C, Zhou X, et al
    One-step percutaneous transhepatic cholangioscopic lithotripsy in patients with choledocholithiasis.
    Clin Res Hepatol Gastroenterol. 2021;45:101477.
    PubMed     Abstract available

  40. YILDIRIM M, Artas H, Artas G
    False-positive PET/CT finding of hepatic inflammatory pseudotumor in IgG4-related sclerosing cholangitis.
    Clin Res Hepatol Gastroenterol. 2021;45:101645.

  41. SHEN X, Huang Y, Guo H, Peng H, et al
    Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
    Clin Res Hepatol Gastroenterol. 2021;45:101495.
    PubMed     Abstract available

    January 2021
  42. LI Y, Hu M, Li L, Liu S, et al
    Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression.
    Clin Res Hepatol Gastroenterol. 2021;45:101525.

  43. KANG Y, Park S, Kim S, Han SJ, et al
    Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
    Clin Res Hepatol Gastroenterol. 2021;45:101437.
    PubMed     Abstract available

    November 2020
  44. ZHAI LL, Xiang F, Wang W, Wu L, et al
    Atypical presentations of coronavirus disease 2019 in a patient with acute obstructive suppurative cholangitis.
    Clin Res Hepatol Gastroenterol. 2020;44:e135-e140.
    PubMed     Abstract available

    October 2020
  45. COUCHONNAL E, Jacquemin E, Lachaux A, Ackermann O, et al
    Long-term results of pediatric liver transplantation for autoimmune liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Oct 16. pii: S2210-7401(20)30275.
    PubMed     Abstract available

  46. RAHAL HK, Tabibian JH
    The MBOAT7 rs641738 variant in primary sclerosing cholangitis: A novel biomarker for prognostication.
    Clin Res Hepatol Gastroenterol. 2020;44:619-621.

    June 2019
  47. RAUBER C, Awad M, Koschny R, Sauer P, et al
    Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are associated with biliary damage and graft survival in a case-control study.
    Clin Res Hepatol Gastroenterol. 2019 Jun 11. pii: S2210-7401(19)30102.
    PubMed     Abstract available

  48. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
    Primary biliary cholangitis in patients with inflammatory bowel disease.
    Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.